Analyzing Anebulo Pharmaceuticals (NASDAQ:ANEB) and REGENXBIO (NASDAQ:RGNX)

REGENXBIO (NASDAQ:RGNX) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares REGENXBIO and Anebulo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-110.29%	-78.29%	-34.49%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Risk & Volatility

REGENXBIO has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.81, suggesting that its share price is 181% less volatile than the S&P 500.

Insider and Institutional Ownership

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 12.8% of REGENXBIO shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for REGENXBIO and Anebulo Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1	1	8	0	2.70
Anebulo Pharmaceuticals	1	1	0	0	1.50

REGENXBIO presently has a consensus target price of $27.80, suggesting a potential upside of 251.90%. Anebulo Pharmaceuticals has a consensus target price of $3.00, suggesting a potential upside of 513.25%. Given Anebulo Pharmaceuticals’ higher probable upside, analysts clearly believe Anebulo Pharmaceuticals is more favorable than REGENXBIO.

Earnings & Valuation

This table compares REGENXBIO and Anebulo Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$83.33 million	4.80	-$227.10 million	($3.47)	-2.28
Anebulo Pharmaceuticals	N/A	N/A	-$8.48 million	($0.19)	-2.57

Anebulo Pharmaceuticals has lower revenue, but higher earnings than REGENXBIO. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Summary

REGENXBIO beats Anebulo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About REGENXBIO

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.